RT Journal Article
T1 Furosemide/Non-Steroidal Anti-Inflammatory Drug-Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulation
A1 Acebedo-Martinez, Francisco Javier
A1 Alarcon-Payer, Carolina
A1 Rodriguez-Domingo, Lucia
A1 Dominguez-Martin, Alicia
A1 Gomez-Morales, Jaime
A1 Choquesillo-Lazarte, Duane
K1 drug-drug cocrystal
K1 furosemide
K1 ethenzamide
K1 piroxicam
K1 mechanochemical synthesis
K1 Co-crystals
K1 Cocrystals
K1 Solubility
K1 Polymorphs
K1 Gefitinib
K1 Selection
K1 Hydrate
K1 Design
K1 Forms
AB The design of drug-drug multicomponent pharmaceutical solids is one the latest drug development approaches in the pharmaceutical industry. Its purpose is to modulate the physicochemical properties of active pharmaceutical ingredients (APIs), most of them already existing in the market, achieving improved bioavailability properties, especially on oral administration drugs. In this work, our efforts are focused on the mechanochemical synthesis and thorough solid-state characterization of two drug-drug cocrystals involving furosemide and two different non-steroidal anti-inflammatory drugs (NSAIDs) commonly prescribed together: ethenzamide and piroxicam. Besides powder and single crystal X-ray diffraction, infrared spectroscopy and thermal analysis, stability, and solubility tests were performed on the new solid materials. The aim of this work was evaluating the physicochemical properties of such APIs in the new formulation, which revealed a solubility improvement regarding the NSAIDs but not in furosemide. Further studies need to be carried out to evaluate the drug-drug interaction in the novel multicomponent solids, looking for potential novel therapeutic alternatives.
PB Mdpi
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/26313
UL https://hdl.handle.net/10668/26313
LA en
DS RISalud
RD Apr 17, 2025